Resources with keywords: monoclonal antibody
Patton ME, Moline HL, Whitaker M, et al.
Interim evaluation of respiratory syncytial virus hospitalization rates among infants and young children in the United States after introduction of respiratory syncytial virus prevention products (e.g., vaccines, long-acting monoclonal antibodies).
Scheppke KA, Pepe PE, et al.
Three individuals with long Covid experienced full remission within a week after monoclonal antibody infusion.
The majority of Omicron sublineages circulating in the United States have reduced susceptibility to the monoclonal antibody, bebtelovimab and the monoclonal antibody combination, cilgavimab and tixagevimab (EvusheldTM). Antiviral therapeutics for the treatment of COVID-19, ritonavir-boosted nirmatrelvir (Paxlovid™), remdesivir (Veklury®), and molnupiravir (Lagevrio™), retain activity against currently circulating Omicron sublineages.
Good summary of vaccine information (elegibility, ages, boosters, side effects, safety, etc.).
